

DAFTAR PUSTAKA

1. Czarnecka-Chrebelska KH, Mukherjee D, Maryanchik S V., Rudzinska-Radecka M. Biological and Genetic Mechanisms of COPD, Its Diagnosis, Treatment, and Relationship with Lung Cancer. *Biomedicines*. MDPI; 2023(11):1–31.
2. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for The Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease (2023 REPORT) [Internet]. 2022. Available from: www.goldcopd.org
3. Biton J, Ouakrim H, Dechartres A, Alifano M, Mansuet-Lupo A, Si H, et al. Impaired tumor-infiltrating t cells in patients with chronic obstructive pulmonary disease impact lung cancer response to PD-1 blockade. *Am J Respir Crit Care Med*. 2018 Oct 1;198(7):928–40.
4. Spyrtos D, Papadaki E, Lampaki S, Kontakiotis T. Chronic obstructive pulmonary disease in patients with lung cancer: Prevalence, impact and management challenges. *Lung Cancer: Targets and Therapy*. 2017 Aug 7;8:101–7.
5. Qi C, Sun SW, Xiong XZ. From COPD to Lung Cancer: Mechanisms Linking, Diagnosis, Treatment, and Prognosis. *International Journal of COPD*. Dove Medical Press Ltd; 2022(17):2603–21.
6. Soriano JB, Zielinski J, Price D. Screening for and early detection of chronic obstructive pulmonary disease. *The Lancet*. Elsevier B.V.; 2009 (374):721–32.
7. Collar DP, Guerra MP, Rodriguez P, Gotera C, Mahillo-Fernández I, Peces-Barba G, et al. COPD is commonly underdiagnosed in patients with lung cancer: Results from the RE COIL study (retrospective study of COPD infradiagnosis in lung cancer). *International Journal of COPD*. 2017 Mar 30;12:1033–8.
8. Mouronte-Roibás C, Leiro-Fernández V, Ruano-Raviña A, Ramos-Hernández C, Abal-Arca J, Parente-Lamelas I, et al. Chronic Obstructive Pulmonary Disease in Lung Cancer Patients: Prevalence, Underdiagnosis, and Clinical Characterization. *Respiration*. 2018 Jul 1;95(6):414–21.
9. Young RP, Hopkins RJ, Christmas T, Black PN, Metcalf P, Gamble GD. COPD prevalence is increased in lung cancer, independent of age, sex and smoking history. *European Respiratory Journal*. 2009 Aug;34(2):380–6.
10. Young RP, Hopkins R. The potential impact of chronic obstructive pulmonary disease in lung cancer screening: implications for the screening clinic. *Expert Review of Respiratory Medicine*. Taylor and Francis Ltd.; 2019(13):699–707.
11. Fathana PB. Prevalens Penyakit Paru Obstruktif Kronik (PPOK) dan Emfisema Berdasarkan Pemeriksaan Spirometri dan Computed

Tomography Scanning (CT-SCAN) Toraks pada Pasien Kanker Paru di Rumah Sakit Umum Pusat Persahabatan. [Jakarta]: Universitas Indonesia; 2019.

12. Yi YS, Ban WH, Sohng KY. Effect of COPD on symptoms, quality of life and prognosis in patients with advanced non-small cell lung cancer. *BMC Cancer*. 2018 Oct 29;18(1):1-8
13. Dai J, Yang P, Cox A, Jiang G. Lung cancer and chronic obstructive pulmonary disease: From a clinical perspective [Internet]. *Oncotarget*. 2017 Mar 14;8(11):18513-24
14. Goffini JR, Corriveau S, Tang GH, Pond GR. Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system. *PLoS One*. 2021 May 1;16(5 May) 1;16:2-10
15. Wang W, Dou S, Dong W, Xie M, Cui L, Zheng C, et al. Impact of COPD on prognosis of lung cancer: From a perspective on disease heterogeneity. *International Journal of COPD*. 2018;13:3767–76.
16. Athlin Å, Lisspers K, Hasselgren M, Stållberg B, Janson C, Montgomery S, et al. Diagnostic spirometry in COPD is increasing, a comparison of two Swedish cohorts. *NPJ Prim Care Respir Med*. 2023 Dec 1;33(1):1-7
17. Ruparel M, Quaife SL, Dickson JL, Horst C, Tisi S, Hall H, et al. Prevalence, symptom burden, and underdiagnosis of chronic obstructive pulmonary disease in a lung cancer screening cohort. *Ann Am Thorac Soc*. 2020 Jul 1;17(7):869–78.
18. Forder A, Zhuang R, Souza VGP, Brockley LJ, Pewarchuk ME, Telkar N, et al. Mechanisms Contributing to the Comorbidity of COPD and Lung Cancer. *International Journal of Molecular Sciences*. MDPI; 2023;24(3):2859
19. Yanev N, Kurtelova N, Mihalova T. Prevalence of copd in patients with lung cancer. *Sciendo*. Sciendo; 2022(49):4–6.
20. Šutić M, Vukić A, Baranašić J, Försti A, Džubur F, Samaržija M, et al. Diagnostic, predictive and prognostic biomarkers in non-small cell lung cancer (Nslc) management. *Journal of Personalized Medicine*. MDPI; 2021;11(11):1102.
21. Thandra KC, Barsouk A, Saginala K, Aluru JS, Barsouk A. Epidemiology of lung cancer. *Wspolczesna Onkologia*. Termedia Publishing House Ltd.; 2021;25(1):45–52.
22. Antariksa B, Wiyono WH, Djajalaksana S, Yunus F, Amin M, Syafiuddin T, et al. Penyakit Paru Obstruktif Kronik (PPOK) Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Antariksa B, Bakhtiar A, Wiyono WH, editors. Jakarta: Perhimpunan Dokter Paru Indonesia ; 2023:hal.10–48.
23. Parris BA, O'Farrell HE, Fong KM, Yang IA. Chronic obstructive pulmonary disease (COPD) and lung cancer: Common pathways for pathogenesis. *Journal of Thoracic Disease*. AME Publishing Company; 2019;11(17): S2155–72.
24. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence

- and Mortality Worldwide for 36 Cancers in 185 Countries. *CA Cancer J Clin.* 2021 May;71(3):209–49.
25. Ajimizu H, Ozasa H, Sato S, Funazo T, Sakamori Y, Nomizo T, et al. Survival impact of treatment for chronic obstructive pulmonary disease in patients with advanced non-small-cell lung cancer. *Sci Rep.* 2021;11(1): 2367726.
 26. Criner GJ, Agusti A, Borghaei H, Friedberg J, Martinez FJ, Miyamoto C, et al. Chronic Obstructive Pulmonary Disease and Lung Cancer: A Review for Clinicians. *Chronic Obstructive Pulmonary Diseases. COPD Foundation;* 2022;9(3): 454–76.
 27. Kamo KI, Katanoda K, Matsuda T, Marugame T, Ajiki W, Sobue T. Lifetime and age-conditional probabilities of developing or dying of cancer in Japan. *Jpn J Clin Oncol.* 2008;38(8):571–6.
 28. Lundbøck B, Lindberg Wz A, Lindstróm W } M, Rúnmark E, Jonsson AC, Júnsson Wz E, et al. Not 15 But 50% of smokers develop COPD? Report from the Obstructive Lung Disease in Northern Sweden Studies. *Respiratory Medicine.* 2003; 97:115-22.
 29. Rosenberger A, Illig T, Korb K, Klopp N, Zietemann V, Wölke G, et al. Do genetic factors protect for early onset lung cancer? A case control study before the age of 50 years. *BMC Cancer.* 2008 Feb 25;8:60-5
 30. Butler SJ, Ellerton L, Goldstein RS, Brooks D. Prevalence of lung cancer in chronic obstructive pulmonary disease: A systematic review. Vol. 1, *Respiratory Medicine: X.* W.B. Saunders Ltd; 2019;1:1-8
 31. Durham AL, Adcock IM. The relationship between COPD and lung cancer. Vol. 90, *Lung Cancer.* Elsevier Ireland Ltd; 2015; 90:121–7
 32. Wang P, Zhu M, Zhang D, Guo X guang, Zhao S, Zhang X lin, et al. The relationship between chronic obstructive pulmonary disease and non-small cell lung cancer in the elderly. *Cancer Med.* 2019;8(9):4124–34.
 33. Kuśnierczyk P, Taucher E, Domagała-Kulawik J. Editorial: Comparison of lung cancer and chronic obstructive pulmonary disease in smokers and never-smokers. Vol. 14, *Frontiers in Immunology.* Frontiers Media S.A.; 2023;14:1143288
 34. Joost O, Wilk JB, Cupples A, Harmon M, Shearman AM, Baldwin CT, et al. Genetic Loci Influencing Lung Function A genomewide Scan in The Framingham Study. *Am J Respir Crit Care Med.* 2002;165:795–9.
 35. Sun X, Shang J, Wu A, Xia J, Xu F. Identification of dynamic signatures associated with smoking-related squamous cell lung cancer and chronic obstructive pulmonary disease. *J Cell Mol Med.* 2020 Jan 1;24(2):1614–25.
 36. Young RP, Hopkins RJ, Gamble GD, Etzel C, El-Zein R, Crapo JD. Genetic evidence linking lung cancer and COPD: A new perspective. *Application of Clinical Genetics.* 2011;4: 99–111.
 37. Ziółkowska-Suchanek I, Mosor M, Gabryel P, Grabicki M, Zurawek M, Fichna M, et al. Susceptibility loci in lung cancer and COPD: Association

- of IREB2 and FAM13A with pulmonary diseases. *Sci Rep.* 2015; 5: 13502.
38. Yang P, Sun Z, Krowka MJ, Aubry MC, Bamlet WR, Wampfler JA, et al. Alpha1-antitrypsin deficiency carriers, tobacco smoke, chronic obstructive pulmonary disease, and lung cancer risk. *Arch Intern Med.* 2008 May 26;168(10):1097–103.
 39. Zhang LY, Sun XW, Ding YJ, Yan YR, Wang Y, Li CX, et al. SERPINA1 Methylation Levels are Associated with Lung Cancer Development in Male Patients with Chronic Obstructive Pulmonary Disease. *International Journal of COPD.* 2022;17:2117–25.
 40. Beermann J, Piccoli MT, Viereck J, Thum T. Non-coding RNAs in Development and Disease: Background, Mechanisms, and Therapeutic Approaches. *Physiol Rev.* 2016;96:1297–325
 41. Keller A, Fehlmann T, Ludwig N, Kahraman M, Laufer T, Backes C, et al. Genome-wide MicroRNA Expression Profiles in COPD: Early Predictors for Cancer Development. *Genomics Proteomics Bioinformatics.* 2018 Jun 1;16(3):162–71.
 42. Wang D, Zhang S, Zhao M, Chen F. LncRNA MALAT1 accelerates non-small cell lung cancer progression via regulating miR-185-5p/MDM4 axis. *Cancer Med.* 2020 Dec 1;9(23):9138–49.
 43. Sun Y, Ma L. New insights into long non-coding rna malat1 in cancer and metastasis. *Cancers.* MDPI AG; 2019; 11(2):216-9
 44. Liao J, Yu L, Mei Y, Guarnera M, Shen J, Li R, et al. Small nucleolar RNA signatures as biomarkers for non-small-cell lung cancer *Mol Cancer.* 2010; 9:198-20
 45. Amsellem V, Gary-Bobo G, Marcos E, Maitre B, Chaar V, Validire P, et al. Telomere dysfunction causes sustained inflammation in chronic obstructive pulmonary disease. *Am J Respir Crit Care Med.* 2011 Dec 15;184(12):1358–66.
 46. Hosgood HD, Cawthon R, He X, Chanock S, Lan Q. Genetic variation in telomere maintenance genes, telomere length, and lung cancer susceptibility. *Lung Cancer.* 2009 Nov;66(2):157–61.
 47. Houghton AMG. Mechanistic links between COPD and lung cancer. *Nature Reviews Cancer.* 2013; 13 (4):233–45.
 48. Mei J, Xiao Z, Guo C, Pu Q, Ma L, Liu C, et al. Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis . *Oncotarget.* 2016; 7 (23):34217-28.
 49. Chang SH, Mirabolfathinejad SG, Katta H, Cumpian AM, Gong L, Caetano MS, et al. T helper 17 cells play a critical pathogenic role in lung cancer. *Proc Natl Acad Sci U S A.* 2014 Apr 15;111(15):5664–9.
 50. Huffnagle GB, Dickson RP, Lukacs NW. The respiratory tract microbiome and lung inflammation: A two-way street. *Mucosal Immunology.* Nature Publishing Group; 2017;10: 299–306.

51. Marshall EA, Filho FSL, Sin DD, Lam S, Leung JM, Lam WL. Distinct bronchial microbiome precedes clinical diagnosis of lung cancer. *Cancer*. BioMed Central Ltd; 2022;21(1):68.
52. Corriveau S, Pond GR, Tang GH, Goffin JR. A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer. 2021;21(1):14 -9
53. Roy E, Rheault J, Pigeon MA, Ugalde PA, Racine C, Simard S, et al. Lung cancer resection and postoperative outcomes in COPD: A single-center experience. *Chron Respir Dis*. 2020;17: 1479973120925430
54. Inoue T, Shiomi H, Oh RJ. Stereotactic body radiotherapy for Stage I lung cancer with chronic obstructive pulmonary disease: Special reference to survival and radiation-induced pneumonitis. *J Radiat Res*. 2015 Jul 1;56(4):727–34.
55. Nardini S, Annesi-Maesano I, Simoni M, Ponte A del, Sanguinetti CM, De Benedetto F. Accuracy of diagnosis of COPD and factors associated with misdiagnosis in primary care setting. E-DIAL (Early DIAGnosis of obstructive lung disease) study group. *Respir Med*. 2018 Oct 1;143:61–6.
56. Global Initiative for Chronic Obstructive Lung Disease Global Strategy for The Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary Disease(2024 REPORT). [Internet]. 2024. Available from:www.goldcopd.org
57. Griffin J, Tolley E, Zaman M, Niell H, Cole F, Weiman D. Chronic obstructive pulmonary disease with lung cancer: Prevalence, severity, and common pathogenesis. *J Cancer Res Ther (Manch)*. 2016 Jan 4;4(1):1–6.
58. Tamási L, Horváth K, Kiss Z, Bogos K, Ostoros G, Müller V, et al. Age and Gender Specific Lung Cancer Incidence and Mortality in Hungary: Trends from 2011 Through 2016. *Pathology and Oncology Research*. 2021 Apr 30;27:598862
59. Wang TW, Asman K, Gentzke AS, et al. Tobacco Product Use Among Adults — United States, 2017. *MMWR Morb Mortal Wkly Rep* 2018;67:1225–1232.
60. Brinkman GL CEO. The effect of bronchitis, smoking, and occupation on ventilation. *Am Rev Respir Dis*. 1963;87(5):684–93.
61. Yunus F. Panduan Pemeriksaan Spirometri. yunus F, editor. Jakarta: UI Publishing; 2022: h.34–53
62. Wibawanto A. Peran Pembedahan untuk Pengobatan Kanker Paru. In: Jusuf A, editor. *Pengobatan Kanker Paru*. Jakarta: Departemen Pulmonologi dan kedokteran Respirasi FKUI; 2019:h 9–10.
63. Casal RF, Sepesi B, Sagar AES, Tschirren J, Chen M, Li L, et al. Centrally located lung cancer and risk of occult nodal disease: An objective evaluation of multiple definitions of tumour centrality with dedicated imaging software. *European Respiratory Journal*. 2019;53(5).

64. Sim YS, Lee JH, Lee WY, Suh DI, Oh YM, Yoon JS, et al. Spirometry and bronchodilator test. *Tuberculosis and Respiratory Diseases. Korean National Tuberculosis Association*; 2017;80: 105–12.
65. Corriveau S, Pond GR, Tang GH, Goffin JR. A population-based analysis of spirometry use and the prevalence of chronic obstructive pulmonary disease in lung cancer. *BMC Cancer*. 2021 Dec 1;21(14):8
66. Apriliana D, Rima Setijadi A. The Role of Incentive Spirometry On Exercise Capacity, Breathing Symptoms, Depression Rate, and Quality of Life in NSCLC Patients with Chemotherapy. *Respir Sci*.2021;2(1):8–17.
67. Kang HS, Park YM, Ko SH, Kim SH, Kim SY, Kim CH, et al. Impaired Lung Function and Lung Cancer Incidence: A Nationwide Population-Based Cohort Study. *J Clin Med*. 2022 Feb 1;11(4):1077
68. Ermayanti S, Afriani A, Nikmawati S, Russilawati R, Medison I, Suyastri S. Gender Disparities in Their Effects on Characteristics and Prognostics of Lung Cancer Patients in Pulmonary Ward of Dr. M Djamil Hospital, Padang. *Jurnal Respirologi Indonesia*. 2021;41(4):245–51.
69. Tolwin Y, Gillis R, Peled N. Gender and lung cancer—SEER-based analysis. *Ann Epidemiol*. 2020 Jun 1;46:14–9.
70. Asmara OD, Tenda ED, Singh G, Pitoyo CW, Rumende CM, Rajabto W, et al. Lung Cancer in Indonesia. *Journal of Thoracic Oncology*. Elsevier Inc.; 2023;18(9):1134–45.
71. Gondhowiardjo S, Christina N, Ngakan ;, Ganapati PD, Hawariy S, Radityamurti F, et al. Five-Year Cancer Epidemiology at the National Referral Hospital: Hospital-Based Cancer Registry Data in Indonesia. *JCO Global Oncol*. 2021;7:190–203.
72. de Groot PM, Wu CC, Carter BW, Munden RF. The epidemiology of lung cancer. *Translational Lung Cancer Research*. AME Publishing Company; 2018;7: 220–33.
73. Arnold BN, Thomas DC, Rosen JE, Salazar MC, Blasberg JD, Boffa DJ, et al. Lung cancer in the very young: Treatment and survival in the national cancer data base. *Journal of Thoracic Oncology*. 2016;11(7):1121–31.
74. Andarini S, Syahrudin E, Aditya N, Zaini J, Kurniawan FD, Ermayanti S, et al. Indonesian Society of Respiriology (ISR) Consensus Statement on Lung Cancer Screening and Early Detection in Indonesia. *Jurnal Respirologi Indonesia*. 2023 Apr 19;43(2):144–50.
75. Travis WD, Brambilla E, Nicholson AG, Yatabe Y, Austin JHM, Beasley MB, et al. The 2015 World Health Organization Classification of Lung Tumors: Impact of Genetic, Clinical and Radiologic Advances since the 2004 Classification. *Journal of Thoracic Oncology*. Elsevier Inc; 2015;10: 1243–60.
76. Zappa C, Mousa SA. Non-small cell lung cancer: Current treatment and future advances. *Transl Lung Cancer Res*. 2016 Jun 1;5(3):288–300.

77. Purdue MP, Gold L, Jarvholm B, Alavanja MCR, Ward MH, Vermeulen R. Impaired lung function and lung cancer incidence in a cohort of Swedish construction workers. *Thorax*. 2007;62:51–6.
78. Cerfolio RJ, Talati A, Bryant AS. Changes in Pulmonary Function Tests After Neoadjuvant Therapy Predict Postoperative Complications. *Annals of Thoracic Surgery*. 2009 Sep;88(3):930–6.
79. Jaeger K, Seppenwoolde Y, Boersma L, Baas P, Balderbos J, Lebesque J. Pulmonary function following high-dose radiotherapy of non-small-cell lung cancer. *Int J Radiat Oncol Biol Phys*. 2003;55(5):1331–40.
80. Gurning AS, Munir SM, Yunus F. Analisis Hubungan antara Jenis dan Stage Kanker Paru dengan Grup Penyakit Paru Obstruksi Kronik (PPOK) Berdasarkan Pemeriksaan Spirometri pada Pasien Kanker Paru di RSUD Arifin Achmad Pekanbaru Provinsi Riau. [Riau]: Fakultas Kedokteran Universitas Riau; 2023.
81. Lamproct B, Soriano J, Studnicka M, Kaiser B, Vanfleteren L, Gnatiuc L. Determinants of underdiagnosis of COPD in national and international surveys. *Chest*. 2015;148:971–85.
82. Butler SJ, Louie A V., Sutradhar R, Paszat L, Brooks D, Gershon AS. Association between COPD and Stage of Lung Cancer Diagnosis: A Population-Based Study. *Current Oncology*. 2023 Jul 1;30(7):6397–410.
83. Nguyen VN, Yunus F, Nguyen TPA, Dao B V, Damayanti T, Wiyono W, et al. The prevalence and patient characteristics of chronic obstructive pulmonary disease in non-smokers in Vietnam and Indonesia: An observational survey. *Respirology*. 2015;20(4):602–11.
84. Bradley C, Alexandris P, Baldwin DR, Booton R, Darby M, Eckert CJ, et al. Measuring spirometry in a lung cancer screening cohort highlights possible underdiagnosis and misdiagnosis of COPD. *ERJ Open Res*. 2023 Jul 1;9(4).
85. Park HY, Kang D, Shin SH, Yoo KH, Rhee CK, Suh GY, et al. Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: A cohort study. *Thorax*. 2020 Jun 1;75(6):506–9.
86. Shin SH, Kim T, Kim H, Cho J, Kang D, Park HY. Impact of smoking reduction on lung cancer risk in patients with COPD who smoked fewer than 30 pack-years: a nationwide population-based cohort study. *Respir Res*. 2024 Dec 1;25(1).
87. Papi A, Casoni G, Caramori G, Guzzinati I, Boschetto P, Ravenna F, et al. COPD increases the risk of squamous histological subtype in smokers who develop non-small cell lung carcinoma. *Thorax*. 2004;59:679–81.
88. Husebø GR, Nielsen R, Hardie J, Bakke PS, Lerner L, D'Alessandro-Gabazza C, et al. Risk factors for lung cancer in COPD – results from the Bergen COPD cohort study. *Respir Med*. 2019 Jun 1;152:81–8.
89. Ju S, Lee HR, Kim JY, Kim HC, Lee GW, You JW, et al. Impact of coexistent chronic obstructive pulmonary disease on the survival of patients with small cell lung cancer receiving chemotherapy. *Thoracic Cancer*. 2018 Oct 1;9(10):1271–8.

90. Li C, Lu H. Adenosquamous carcinoma of the lung. Vol. 11, OncoTargets and Therapy. Dove Medical Press Ltd.; 2018. p. 4829–35.
91. Mohan A, Mohan C, Pathak AK, Pandey RM, Guleria R. Impact of chronic obstructive pulmonary disease on respiratory status and quality of life in newly diagnosed patients with lung cancer. *Respirology*. 2007 Mar 13;12(2):240–7.
92. Nguyen HV, Byeon H. Prediction of ECOG Performance Status of Lung Cancer Patients Using LIME-Based Machine Learning. *Mathematics*. 2023 May 1;11(10).
93. Wilson DO, Weissfeld JL, Balkan A, Schragin JG, Fuhrman CR, Fisher SN, et al. Association of radiographic emphysema and airflow obstruction with lung cancer. *Am J Respir Crit Care Med*. 2008 Oct 1;178(7):738–44.
94. Maninno D, Aguayo S, Petty T, Redd S. Low Lung Function and Incident Lung Cancer in the United States: Data From the First National Health and Nutrition Examination Survey Follow-up. *Arch Intern Med*. 2003;163(12):1475–148.
95. Gagnat AA, Gjerdevik M, Lie SA, Gulsvik A, Bakke P, Nielsen R. Acute exacerbations of COPD and risk of lung cancer in COPD patients with and without a history of asthma. *Eur Clin Respir J*. 2020 Jan 1;7(1).
96. Papi A, Bellettato CM, Braccioni F, Romagnoli M, Casolari P, Caramori G, et al. Infections and airway inflammation in chronic obstructive pulmonary disease severe exacerbations. *Am J Respir Crit Care Med*. 2006 May 15;173(10):1114–21.
97. Bozinovski S, Vlahos R, Anthony D, McQualter J, Anderson G, Irving L, et al. COPD and squamous cell lung cancer: Aberrant inflammation and immunity is the common link. *British Journal of Pharmacology*. John Wiley and Sons Inc.; 2016;173: 638–48.
98. Zhai T, Li Y, Brown R, Lanuti M, Gainor JF, Christiani DC. Spirometry at diagnosis and overall survival in non-small cell lung cancer patients. *Cancer Med*. 2022 Dec 1;11(24):4796–805.
99. Sanchez-Salcedo P, Berto J, De-Torres JP, Campo A, Alcaide AB, Bastarrika G, et al. Lung Cancer Screening: Fourteen Year Experience of the Pamplona Early Detection Program (P-IELCAP) *Arch Bronconeumol*. 2015;51:465
100. Supriyana I, Yunus F, Antariksa B, Kekalih A. Studi Longitudinal Faktor Prediksi Indeks BODE pada Pasien Penyakit paru Obstruktif Kronik di Rumah Sakit Persahabatan Jakarta. *J Respir Indo*. 2019;39(4):220–5.
101. Tantucci C, Modena D. Lung function decline in COPD. *International Journal of COPD*. 2012;7: 95–9.
102. Machida H, Inoue S, Shibata Y, Kimura T, Ota T, Ishibashi Y, et al. The incidence and risk analysis of lung cancer development in patients with chronic obstructive pulmonary disease: Possible effectiveness of annual ct-screening. *International Journal of COPD*. 2021;16:739–49.

103. De Torres JP, Marín JM, Casanova C, Cote C, Carrizo S, Cordoba-Lanus E, et al. Lung cancer in patients with chronic obstructive pulmonary disease: Incidence and predicting factors. *Am J Respir Crit Care Med*. 2011 Oct 15;184(8):913–9.
104. Lim JU, Yeo CD, Rhee CK, Kim YH, Park CK, Kim JS, et al. Chronic obstructive pulmonary disease- related non-small-cell lung cancer exhibits a low prevalence of EGFR and ALK driver mutations. *PLoS One*. 2015 Nov 10;10(11).
105. Vitor M, Carvalho L. Heterogeneity in Lung Cancer. *Pathobiology*. Karger. 2018; 85 (1-2): 96–107

